Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study
Clinical Cancer Research · 2026-06-25
Lorlatinib vs crizotinib as first-line treatment for advanced <i>ALK</i> + non-small cell lung cancer: 7-year update from the phase 3 CROWN study.
Journal of Clinical Oncology · 2026-05-28
Abstract CT248: Zidesamtinib in patients with ROS1+ NSCLC previously treated with repotrectinib or taletrectinib
Cancer Research · 2026-04-17
Abstract 6473: Clonal consolidation and transcriptional re-programming define non-small cell lung cancers resistant to immune checkpoint inhibitors
Cancer Research · 2026-04-03
Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancer
Lung Cancer · 2026-01-27
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non–small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors
Lung Cancer · 2025-11-28 · 1 citations
MA01.04 Neoadjuvant PD-(L)1 Blockade in Combination With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer
Journal of Thoracic Oncology · 2025-10-01
Supplemental Table 1 from Response and Resistance to RAS Inhibition in CancerPreprint
2025-07-03
Data from Response and Resistance to RAS Inhibition in CancerPreprint
2025-07-03
Young lung cancer: from diagnosis to survivorship
Frontiers in Oncology · 2025-06-26 · 2 citations
Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study.
Journal of Clinical Oncology · 2025-05-28 · 5 citations
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer
JAMA Oncology · 2025-05-22 · 24 citations
Response and Resistance to RAS Inhibition in Cancer
Cancer Discovery · 2025-04-28 · 36 citations
1691 A Complementary Role for Immunohistochemistry and NGS for Detection of MTAP Gene Deletion in Patients with Non-Small Cell Lung Cancer
Laboratory Investigation · 2025-03-01 · 3 citations
Strengthening Asian/Asian American, Native Hawaiian, and Pacific Islander Leadership in Cancer Research
Cancer Discovery · 2025-02-07 · 2 citations
Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study
Lung Cancer · 2024-11-01 · 8 citations
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer
Future Oncology · 2024-10-03 · 1 citations